Serpins, the vasculature, and viral therapeutics

Frontiers in Bioscience

Volumn 11, Issue 1 P.889-1198, 2006, Pages 1042-1056

  Richardson, Jakob ^a,b   Viswanathan, Kasinath ^a   Lucas, Alexandra ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Innate Immunity; Review; Serpins; Thrombolysis; Thrombosis; Vessel

Indexed keywords

ANIMALIA; MAMMALIA; MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 32944461502     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1862     Document Type: Review

References (147)

1. Fagiotto A, R. Ross: Studies of hypercholesterolemia in non-human primates. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 4(4), 341-56 (1984)
2. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 340, 115-26 (1999)
3. Fuster V, L. Badimon, J. J. Badimon, J. H. Chesebro: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med 326, 310-318 (1996)
4. Fuster V, Z. A. Fayad, J. J. Badimon: Acute coronary syndromes: Biology. Lancet 353(suppl 2), SII5-SII9 (1999)
5. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104, 365-372 (2001)
6. Poole J C F, H. W. Florey: Changes in the endothelium of the aorta and the behavior of macrophages in experimental aheroma of rabbits. J Pathol Bacteriol 75, 245-253 (1958)
7. Cybulsky M I, M. A. Gimbrone: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251, 788-791 (1991)
8. Walpola P L, A. I. Gotlieb, M. I. Cybulsky, B. L. Langille: Expression of ICAM-1 and VCAM01 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler Thromb Vasc Biol 15, 2-10 (1995)
9. Li H, M. I. Cybulsky, M. A. Gimbrone, P. Libby: An antherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler Thromb 13, 197-204 (1993)
10. Johnson R C, S. M. Chapman, Z. M, Dong, J. M. Ordovas, T. N. Mayadas, J. Herz, R. O, Hynes, E. J. Schaefer, D. D. Wagner: Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 99, 1037-1043 (1997)
11. Dong Z M, S. M. Chapman, A. A. Brown, P. S. Frenette, R. O. Hynes, D. D. Wagner: The combined role of P and E selectins in atherosclerosis. J Clin Invest 102, 145-152 (1998)
12. Faustmann P M, R. Dermietzel, Extravasation of polymorphonuclear leukocytes from the cerebral microvasculature. Inflammatory response induced by alpha-bungarotoxin. Cell Tissue Res 242, 399-407 (1985)
13. Feng D, J. A. Nagy, K. Pyne, H. F. Dvorak, A. M. Dvorak: Neutrophil emigration from venules by a transendothelial cell pathway in response to fMLP. J Exp Med 187, 903-915 (1998)
14. Furie M B, B. L. Naprstek, S. C. Silverstein: Migration of neutrophils across monolayers of cultured microvascular endothelial cells. An in vitro model of leukocyte extravasation. J Cell Sci 88, 161-175 (1987)
15. Hoshi O, T. Ushiki: Scanning electron microscopic studies of the route of neutrophil extravasation in the mouse after exposure to the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP). Arch Histol Cytol 62, 253-260 (1999)
16. Boring L, J. Gosling, M. Cleary, I. F. Charo: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897 (1998)
17. Boisvert W A, R. Santiago, L. K. Curtiss, R. A. Terkeltaub: A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 101, 353-363 (1998)
18. Combadiere C, S. Potteaux, J. L. Gao, B. Esposito, S. Casanova, E. J. Lee, P. Debre, A. Tedgui, P. M. Murphy, Z. Mallat: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 25;107(7), 109-16 (2003)
19. Smith J D, E. Trogan, M. Ginsberg, C. Grigaux, J. Tian, M. Miyata: Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein. Eur Proc Natl Acad Sci USA 92, 8264-8268 (1995)
20. Clinton S, R. Underwood, M. Sherman, D. Kufe, P. Libby: Macrophage colony stimulating factor gene expression in vascular cells and in experimental and human athersclerosis. Am J Pathol 140, 301-316 (1992)
21. Rosenfeld M E, S. Yla-Herttuala, B. A. Lipton, V. A. Ord, Witztum J. L., D. Steinberg: Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol 140, 291-300 (1992)
22. Geng Y J, G. K. Hannsson: Interferon-gamma scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J Clin Invest 89, 1322-1330 (1992)
23. Van Lenten B J, A. M. Fogelman: Lipopolysaccharide-induced inhibition of scavenger receptor expression in human monocyte-macrophages os mediated through tumor necrosis factor-alpha. J Immunol 148, 112-116 (1992)
24. Liao H S, A. Matsumoto, H. Itakura, T. Doi, M. Honda, T. Kodama, Y. J. Geng: Transcriptional inhibition by interleukin-6 of the class A macrophage scavenger receptor in macrophages derived from human peripheral monocytes and the THP-1 monocytic cell line. Arterioscl Thomb Vasc Biol 19, 1872-1880 (1999)
25. Varela O, J. Martinez-Gonzalez, L. Badimon: The response of smooth muscle cells to "alpha" thrombin depends on its arterial: comparison among different species. Eur J Clin Invest 28, 313-323 (1998)
26. Bar-Shavit R, M. Benezra, V. Sabbah, W. Bode, I. Vlodavsky: Thrombin as a multi-functional protein: induction of cell adhesion and proliferation. Am J Respir Cell Mol Biol 6, 123-130 (1992)
27. Kanthou C, O. Benzakour: Cellular effects of thrombin and their signalling pathways. Cell Pharmacol 2, 293-302 (1995)
28. Pearson J D: Endothelial cell function and thrombosis. Baillieres Clin Haematol 7, 441-452 (1994)
29. Schwartz S M, D. de Blois, E. R. O'Brien: The intima: Soil for atherosclerosis and restenosis. Circ Res 77, 445-465 (1995)
30. Stary H C, A. B. Chandler, R. E. Dinsmore, V. Fuster, S. Glagov, W. Insull, M. E. Rosenfeld, C. J. Schwartz, W. D. Wagner, R. W. Wissler: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92, 1355-1374 (1995)
31. Pendurthi U R, D. Alok, L. V. Rao: Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: upregulation of poly(A) polymerase. Proc Nat Acad Sci USA 94, 12598-12603 (1997)
32. Taniguchi T, A. K. Kakkar, E. G. D. Tuddenham: Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 58, 4461-4467 (1998)
33. Cirillo P, G. Cali, P. Golino, P. Calabro, L. Forte, S. De Rosa, M. Pacileo, M. Ragni, F. Scopacasa, L. Nitsch, M. Chiariello: Tissue Factor, Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal Regulated Kinase Activation. Circulation 109, 2911-2916 (2004)
34. Eaton D, H. Rodriguez, G. A. Vehar: Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of Factor VIII coagulant activity. Biochemistry 25, 505-512 (1986)
35. Esmon C T, N. L. Esmon, B. F. LeBonniec, A. E. Johnson: Protein C activation. Methods Enzymol 222, 359-385 (1993)
36. Jenny N S, K G Mann: Coagulation cascade: an overview. In: Thrombosis and Hemorrhage, Eds: Loscalzo J, Shafer A I, Williams & Wilkins, Baltimore (1998)
37. Vassalli J D, A. P. Sappino, D. Belin: The plasminogen activator/plasmin system. J Clin Invest 88, 1067-1072 (1991)
38. Shen G X: Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders [review]. Int J Mol Med 1, 399-408 (1998)
39. Lijnen H R, B. VanHoef, F. Lupu, L. Moons, P. Carmeliet, D. Collen: Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinoloytic system of genes. Arterioscler Thrombosis 18, 1035-1045 (1998)
40. Steffanson S, C. C. Haudenschild, D. A. Lawrence: Beyond fibrinolysis: The role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med 8, 175-180 (1998)
41. Carmeliet P, D. Collen: Genetic analysis of the plasminogen and coagulation system in mice. Haemostasis 26(4), 132-153 (1996)
42. Bugge T H, M. J. Flick, M. J. Danton, C. C. Daugherty, J. Romer, K. Dano, P. Carmeliet, D. Collen, J. L. Degen: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Nat Acad Sci USA 93, 5899-5904 (1996)
43. Carmeliet P, D. Collen: Molecular analysis of blood vessel formation and disease. Am J Physiol 273, H2091-2104 (1997)
44. Dewerchin M, A. V. Nuffelen, G. Wallays, A. Bouch, L. Moons, P. Carmeliet: Generation and characterization of urokinase-deficient mice. J Clin Invest 97, 870-878 (1996)
45. Blasi F: uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive, and chemotactic highways? Trends Immunol 18, 415-7 (1997)
46. Silverman G A, P. I. Bird, R. W. Carrell, F. D. Church P. B. Coughlin, P. G. W. Gettins, J. A. Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, P. A. Pemberton, E. Remold-O'Donnell, G. S. Salvesen, J. Travis, J. C. Whisstock: The serpins are an expanding superfamily of similar but functionally diverse proteins. J Biol Chem 276, 33293-33296 (2001)
47. Zalai C V, P Nash, E Dai, L Liu & A Lucas: In: Cardiovascular Plaque Rupture. Eds: Brown D L, Marcel Decker Inc., NY (2002)
48. Reidy M A, C. Irvin, V. Lindner: Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 78, 405-414 (1996)
49. Chang A W, A. Kuo, E. S. Barathan, S. S. Okada: Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase, Arterioscler Thromb Vasc Biol 18, 1855-1860 (1998)
50. Germer M, S. M. Kanse, B. Yutzy, L. Kjoller, B. Felding-Habermarm, S. Goodman, K. T. Preissner: Kinetic anaylsis of integrin-dependent cell adhesion on vitronectin - the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides, Eur J Biochem 253, 669-674 (1998)
51. Chavakis T, S. M. Kanse, B. Yutzy, H. R. Lijnen, K. T. Preissner: Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91, 2305-2312 (1998)
52. Falcone D J, T. A. McCaffrey, A. Haimovitz-Friedman, J. A. Vergilio, A. C. Nicholson: Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation, J Biol Chem 268, 11951-11958 (1993)
53. Nikkari S T, H. G. Welgus, K. D. O'Brien, C. E. Alpers, M. Ferguson, A. W. Clowes, T. Hatsukami: Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 92: 1393-1398 (1995)
54. Bruschke A V, J. R. Kramer, E. T. Bal, I. U. Haque, R. C. Detrano, M. Goormastic: The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am Heart J 117, 296-305 (1989)
55. Yokoya K, H. Takatsu, T. Suzuki, H. Hosokawa, S. Ojio, T. Matsubara, T. Tanaka, S. Watanabe, N. Monta, K. Nishigaki, G. Takemura, T. Noda, S. Minatoguchi: Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: a study based on four serial coronary arteriograms per year. Circulation 100: 903-909 (1999)
56. Lendon C L, M. J. Davies, G. V. Born, P. D. Richardson: Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 87(1), 87-90 (1991)
57. van der Wal A C, A. E. Becker, C. M. van der Loos, P. K. Das: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology, Circulation 89(1), 36-44 (1994)
58. Amento E P, N. Ehsani, H. Palmer, P. Libby: Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arteriosclerosis 11, 1223-1230 (1991)
59. Dollery C M, J. R. McEwan, A. Henney: Matrix metalloproteinases and cardiovascular disease. Circ Res 77, 863-8 (1995)
60. Libby P: The molecular bases of the acute coronary syndromes. Circulation 91, 2844-2850 (1995)
61. Geng Y J, P. Libby: Evidence for apoptosis in advanced atheroma: Co-localization with interleukin-1 beta-converting enzyme. Am J Pathol 147, 251-266 (1995)
62. Bendeck M P, C. Irvin, M. A. Reidy: Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 78, 38-43 (1996)
63. Kovanen P T, M. Kaartinen, T. Paavonen: Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92(5), 1084-8 (1995)
64. Arbustini E, P. Morbini, B. D. Bello, F. Prati, G. Specchia: From plaque biology to clinical setting. Am Heart J 138(2 pt 2), S55-60 (1999)
65. Arbustini E, B. Dal Bello, P. Morbini, A. P. Burke, M. Bocciarelli, G. Specchia, R. Virmani: Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82(3), 269-72 (1999)
66. Galis Z, G. Sulhova, M. Lark, P. Libby: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic piques. J Clin Invest 94, 2493-2503 (1994)
67. Haas T L, S. J. Davis, J. A. Madri: Three dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 273(6), 3604-10 (1998)
68. Saren P, H. G. Welgus, P. T. Kovanen: TNF-alpha and IL-1beta selectively induce expression of 92 kDa gelatinase by human macrophages. J Immunol 157, 4159-4165 (1996)
69. Kovanen P T, M. Kaartinen, T. Paavonen: Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92, 1084-1088 (1995)
70. Brogi E, J. A. Winkles, R. Underwood, S. K. Clinton, G. F. Alberts, P. Libby: Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and non-atherosclerotic arteries: association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 92, 2408-2418 (1993)
71. Ramos M A, M. Kuzuya, T. Esaki, S. Miura, S. Satakes, T. Asai, S. Kanada, T. Hayashi, A. Iguchi: Induction of macrophage VEGFs in response to oxidized LDL and VEGF accumulation in human atherosclerosis lesions. Arterioscler Thromb Vasc Biol 18, 1188-1196 (1998)
72. Iacovos P, G. Sotiropoulou, G. Pampalakis, A. Magklara, M. Ghosh, G. Wasney, E. P. Diamandis: Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression. J Biol Chem 285 (15), 14628-14635 (2005)
73. Moulton K S, E. Heller, M. A. Konerding, E. Flynn, W. Palinski, J. Folkman: Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99, 1726-1732 (1999)
74. Roberts T H, J. Hejgaard, N. F. Saunders, R. Cavicchioli, P. M. Curmi: Serpins in unicellular Eukarya, Archae, and Bacteria: sequence analysis and evolution. J Mol Evol 59(4), 437-47 (2004)
75. Irving J A, R. N. Pike, A. M. Lesk, J. C. Whisstock: Phylogeny of the serpin superfamily: implications of patterns of amino acid conversation for structure and function. Genome Res 10, 1845-1864 (2000)
76. Schick C, P. A. Pemberton, G. P. Shi, Y. Kamachi, S. Cataltepe, A. J. Bartuski, E. R. Gornstein, D. Bromme, H. A. Chapman, G. A. Silverman: Cross-class inhibiton of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 37: 5258-5266 (1998)
77. Potempa J, E. Korzus, J. Travis: The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 269, 15957-15960 (1994)
78. Patson P A: Serpins and other serine protease inhibitors. Immunol Today 21(7), 354 (2000)
79. Scott F L, H. J. Eyre, M. Lioumi, J. Ragoussis, J. A. Irving, G. A. Sutherland, P. I. Bird: Human ovalbumin serpin evolution: phylogenic analysis, gene organization, and identification of new PI8 related genes suggest that two interchromosomal and several intrachromosomal duplications generated the gene clusters at 18q21-q23 and 6p25. Genomics 62, 490-499 (1999)
80. Chuang T L, R. R. Schleef: Identification of a nuclear targeting domain in the isertion between helices C and D in protease inhibitor-10. J Biol Chem 274, 11194-11198 (1999)
81. Dahlen J R, D. C. Foster, W. Kisiel: Human proteinase inhibitor 9 (PI9) is a potent inhibitor of subtilisin A. Biochem Biophys Res Commun 238: 329-333 (1997)
82. Dahlen J R, F. Jean, G. Thomas, D. C. Foster, W. Kisiel: Inhibition of soluble recombinant furin by human proteinase inhibitor 8. J Biol Chem 273: 1844-1851 (1998)
83. Lucas A, E. Dai, L. Liu, H. Guan, P. Nash, G. McFadden, L. Miller: Transplant Vasculopathy: Viral Anti-Inflammatory Serpin Regulation of Atherogenesis. J Heart Lung Transplant 19, 1029-1038 (2000)
84. Eren M, C. A. Painter, J. B. Atkinson, P. J. Declerck, D. E. Vaughan: Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106: 491-496 (2002)
85. Collet J P, G. Montalescot, E. Vicaut, A. Ankri, F. Walylo, C. Lesty, R. Choussat, F. Beygui, M. Borentain, N. Vignolles, D. Thomas: Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108, 391-394 (2003)
86. Hamsten A, U. de Faire, G. Walldius, G. Dahlen, A. Szamosi, C. Landou, M. Blomback, B. Wiman: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet II, 3-9 (1987)
87. Juhan-Vague I, S. D. M. Pyke, M. C. Alessi, J. Jespersen, F. Haverkate, S. G. Thompson: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94: 2057-2063 (1996)
88. Anand S S, Q. Yi, H. Gerstein, E. Lonn, R. Jacobs, V. Vuksan, K. Veo, B. Davis, P. Montague, S. Yusuf: Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aborignal Peoples Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108, 420-425 (2003)
89. Thorgersen A M, J. H. Jansson, K. Boman, T. K. Nilsson, L. Weinehall, F. Huhtasaari, G. Hallmans: High plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidences or the fibrinolytic system as an independent primary risk factor. Circulation 98, 2241-2247 (1998)
90. Sobel B E, J. Woodcock-Mitchell, D. J. Schneider, R. E. Holt, K. Marutska, H. Gold: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with non-diabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 97, 2213-2221 (1998)
91. DeYoung M B, C. Tom, D. A. Dichek: Plasminogen activator inhibitor type 1 increases neointima formation in balloon injured rat carotid arteries. Circulation 104: 1972-1981 (2001)
92. Yepes M, M. Sandkvist, M. K. Wong, T. A. Coleman, E. Smith, S. L. Cohan, D. A. Lawrence: Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia induced apoptosis. Blood 96, 569-576 (2000)
93. Bajou K, A. Noel, R. D. Gerard, V. Masson, N. Brunner, C. Holst-Hansen, M. Skobe, N. E. Fusenig, P. Carmeliet, D. Collen, J. M. Foidart: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 4(8), 923-8 (1998)
94. Daniel T E, R. J. Westrick, Z. Xu, J. Tyson, D. Ginsburg: Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. BLOOD 96 (13), 4212-4215 (2000)
95. Ness K V, V. Chobaz-Peclat, M. Castellucci, A. So, N. Busso: Plasminogen activator inhibitor type I deficiency attenuates murine antigen-induced arthritis. Rheumatol. 41, 136-141 (2002)
96. Zhu Y, P. Carmeliet, W. P. Fay: Plasminogen Activator Inhibitor-1 Is a Major Determinant of Arterial Thrombolysis Resistance. Circulation 99, 3050-3055 (1999)
97. 1-42 Binds to Two b-Sheets of a1-antichymotrypsin and Transforms It From Inhibitor to Substrate. J Biol Chem 273(43), 28360-28364 (1998)
98. Chorostowska-Wynimko J, E. Skrzypczak-Jankun, J. Jankun: Plasminogen activator inhibitor type-1 controls the process of the in vitro sprout formation. J Phys Pharm 55(3), 49-56 (2004)
99. Chorostowska-Wynimko J, R. Swiercz, E. Skrzypczak-Jankun, S. H. Selman, J. Jankun: Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncol Rep 12(6), 1155-62 (2004)
100. Bajou K, C. Maillard, M. Jost, R. H. Lijnen, A. Gils, P. Declerck, P. Carmeliet, J. M. Foidart, A. Noel: Host derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23(41): 6986-90 (2004)
101. Dawson D W, O. V. Volpert, P. Gillis, S. E. Crawford, H. Xu, W. Benedict, N. P. Bouck: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248 (1999)
102. Carmeliet P, L. Moons, M. Dewerchin, N. Mackman, T. Luther, G. Breier, V. Ploplis, M. Muller, A. Nagy, E. Plow, R. Gerard, T. Edgington, W. Risau, D. Collen: Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci 811, 191-206 (1997)
103. Zhang M, O. V. Volpert, Y. H. Shi, N. Bouck: Maspin is an angiogenesis inhibitor, Nat Med 6, 196-199 (2000)
104. Stefansson S, E. Petitclerc, M. K. K. Wong, G. A. McMahon, P. C. Brooks, D. A. Lawrence: Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1, J Biol Chem 276, 8135-8141 (2001)
105. O'Reilly M S, S. Pirie-Shepherd, W. S. Lane, J. Folkman: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285, 1926-1928 (1999)
106. Carrell R W, P. A. Pemberton, D. R. Boswell, The serpins: evolution and adaptation in a family of protease inhibitors. Cold Spring Harb Symp Quant Biol LII, 527-535 (1987)
107. Gettins G W P: Keep the serpin machine running smoothly. Genome Res 10, 1833-1835 (2000)
108. Huntington J A, R. J. Read, R. W. Carroll: Structure of a serpin-protease complex shows inhibition by deformation. Nature 407, 923-926 (2000)
109. Gabriel C, C. Ali, S. Lesne, M. Fernandez-Monreal, F. Docagne, L. Plawinski, E. T. MacKenzie, A. Buisson, D. Vivien: Transforming growth factor alpha-induced expression of type 1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxcicity, FASEB J 17(2), 277-9 (2003)
110. Simas J P, R. J. Bowden, V. Paige, S. Efstathiou: Four tRNA like sequences and a serpin homologue encoded by murine gammaherpesvirus 68 are dispensable for lytic replication in vitro and latency in vivo. J Gen Virol 79 (Pt 1), 149-153 (1998)
111. Macen J L, C. Upton, N. Nation, G. McFadden: SERP-1, a serine protease inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 195, 348-363 (1993)
112. Turner P C, R. W. Moyer: Orthopoxvirus fusion inhibits glycoprotein SPI-3 (open reading frame K2L) contains motifs characteristic of serine proteinase inhibitors that are not required for control of cell fusion. J Virol 69(10), 5978-5987 (1995)
113. O'Donoghue D J, M. Guickian, G. Blundell, R. J. Winnery: Alpha-1-proteinase inhibitor and pulmonary haemorrhage in systemic vasculitis. Adv Exp Med Biol 336, 331-5 (1993)
114. Owen M C, S. O. Brennan, J. H. Lewis, R. W. Carrell: Mutation of antitrypsin. Alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 309(12), 694-8 (1983)
115. Stein P E, R. W. Carrell: What do dysfunction serpins tell us about molecular mobility and disease? Nat Struct Biol [Review] 2, 96-113 (1995)
116. Elliott P R, D. A. Lomas, R. W. Carrell, J. P. Abrahams: Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat Struct Biol 3, 676-681 (1996)
117. Onda M, D. Belorgey, L. K. Sharp, D. A. Lomas: Latent S49P neuroserpin forms polymers in the dementia familial encephalopathy with neuroserpin inclusion bodies. J Biol Chem 280(14), 13735-41 (2005)
118. Gettins P G W, P. A. Patston, S. T. Olson: Serpins: Structure, Function, and Biology. Eds: Gettins PGW, Patston P A, Olson S T, Molecular Biology Intelligence Unit, R. G. Landes Co. and Chapman & Hall, Austin TX (1996)
119. Huntington J A, R. J. Read, R. W. Carrell: Structure of a serpin-protease complex shows inhibition by deformation. Nature 407(6806), 923-6(2000)
120. Carrell R W, D. L. Evans, P. E. Stein: Mobile reactive centre of serpins and the control of thrombosis. Nature 353(6344), 576-8
121. Schwartz B S, F. Espana: Two distinct urokinase-serpin interactions regulate the initiation of cell surface associated plasminogen. J Biol Chem 274(21), 15278-83(1999)
122. Schich B H, J. Potempa, J. Travis: The use of alpha-2-antiplasmin as a model for the demonstration of complex reversibility in serpins. J Biol Chem 264(23), 13420-3(1989)
123. Alcami A, U. H. Koszinowski: Viral mechanisms of immune evasion. Immunol Today 21, 447-55 (2000)
124. Alcami A: Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3, 36-50 (2003)
125. Lucas A, G. McFadden: Secreted Immunomodulatory Viral Proteins as Novel Biotherapeutics. J Immunol 173(8), 4765-4774 (2004)
126. Upton C, S. Slack, A. L. Hunter, R. L. Ehlers: Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J Virol 77, 7590-600 (2003)
127. McLysaght A, P. F. Baldi, B. S. Gaut: Extensive gene gain associated with adaptive evolution of poxvirus genome. Proc Nal Acad Sci 100, 15655-60 (2003)
128. Gubser C, S. Hue, P. Kellam, G. L. Smith, Poxvirus genomes: a phylogenetic analysis. J Gen Virol 85, 105-117 (2004)
129. Nash P, A. Lucas, G. McFadden: Serp-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. In: Chemistry and Biology of Serpins. Eds: Church F., Plenum Press, NY (1997)
130. Nash P, M. Barry, B. T. Seet, K. Veugelers, S. Hota, J. Heger, C. Hodgkinson, K. Graham, R. J. Jackson, G. McFadden: Post-translational modification of the myxoma-virus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase. Biochem J 347, 375-382 (2000)
131. Lomas D A, D. L. Evans, C. Upton, G. McFadden, R. W. Carrell: Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. J Biol Chem 268(1), 516-21
132. Upton C, J. L. Macen, D. S. Wishart, G. McFadden: Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology 179, 618-631 (1990)
133. Nash P, A. Whitty, J. Handwerker, J. Macen, G. McFadden: Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J Biol Chem 273, 20982-20991 (1998)
134. Lucas A, L. Liu, J. L. Macen, P. D. Nash, E. Dai, M. Stewart, W. Yan, K. Graham, W. Etches, L. Boshkov, P. N. Nation, D. Humen, M. Hobman, G. McFadden: A virus-encoded serine proteinase inhibitor, Serp-1, inhibits atherosclerotic plaque development following balloon angioplasty. Circulation 94, 2890-2900 (1996)
135. Bot I, J. H. von der Thusen, M. M. Donners, A. Lucas, M. L. Fekkes, S. C. de Jager, J. Kuiper, M. J. Daemen, T. J. van Berkel, S. Heeneman, E. A. Biessen: Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res 93(5), 464-471 (2003)
136. Miller L W, E. Dai, P. Nash, L. Liu, C. Icton, D. Klironomos, L. Fan, P. N. Nations, R. Zhong, G. McFadden, A. Lucas: Inhibition of Transplant Vasculopathy in a Rat Aortic Allograft Model After Infusion of Anti-Inflammatory Viral Serpin. Circulation 101, 1598-1605 (2000)
137. Hausen B, K. Boeke, G. J. Berry, R. E. Morris: Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. Transplantation 72, 364-368 (2001)
138. Alessi M C, I. Juhan-Vague: Contribution of PAI-1 in cardiovascular pathology, Arch Mal Coeur Vaiss 97, 673-678 (2004)
139. Luttun A, F. Lupu, E. Storkebaum, M. F. Hoylaerts, I. Moon, J. Crawley, F. Bono, A. R. Poole, P Tipping, J. M. Herbert, D. Collen, P. Carmeliet: Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 22, 499-505 (2002)
140. Ploplis V A, I. Comelissen, M. J. Sandoval-Cooper, L. Weeks, F. A. Noria, F. Castellino: Remodeling of the Vessel Wall after Copper-Induced Injury Is Highly Attentuated in Mice with a Total Deficiency of Plasminogen Activator Inhibitor-1, Am J Pathol 158, 1 107-117 (2001)
141. Schneiderman J, M. S. Sawdey, M. R. Keeton, G. M. Bordin, E. F. Bernstein, R. B. Dilley, D. J. Loskutoff: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Nat Acad Sci 89, 6998-7002 (1992)
142. Lupu F, G. E. Bergonzelli, D. A. Heim, E. Cousin, C. Y. Genton, F. Bachmanri, E. K. Kruithof: Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 13, 1090-1100 (1993)
143. Chomiki N, M. Henry, M. C. Alessi, F. Anfosso, I. Juhan-Vague: Plasminogen activator inhibitor-1 expression in human liver and health or atherosclerotic vessel walls. Thromb Haemost 72, 44-53 (1994)
144. Carmeliet P, L. Moons, V. Plolis, E. Plow, D. Collen: Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 99, 200-208 (1997)
145. Dai E, H. Guan, L. Liu, S. Little, G. McFadden, S. Vaziri, H. Cao, I. A. Ivanova, L. Bocksch, A. Lucas: Serp-1, a viral anti-inflammatory serpin regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem 278, 18563-18572 (2003)
146. Christov A, R. M. Korol, E. Dai, L. Liu, H. Guan, M. A. Bernards, P. B. Cavers, D. Susk, A. Lucas: In Vivo Optical Analysis of Quantitative Changes in Collagen and Elastin During Arterial Remodeling. Photochem Photobiol 81, 457-466 (2005)
147. Maksymowych W P, N. Nation, P. Nash, J. Macen, A. Lucas, G. McFadden, A. S. Russell: Amelioration of antigen induced arthritis in rabbits treat with a secreted viral serine proteinase inhibitor. J Rhematol 23(5), 878-882 (1996)